Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Harbeck

Showing results (31-40 of 148) with videos related to

Pageof 15
Sort By:
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|March 19, 2014
Timing of radiotherapy following breast-conserving surgery: outcome of 1393 patients at a single institutionS Corradini, O M Niemoeller, M Niyazi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 23, 2017
Pooled analysis of two randomized, double-blind trials comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancerK Blackwell, P Gascon, C M Jones, et al.
Oncology Reports|April 6, 2006
Application of intrathecal trastuzumab (Herceptintrade mark) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancerH J Stemmler, M Schmitt, N Harbeck, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 12, 2007
Management of venous port systems in oncology: a review of current evidenceS Vescia, A K Baumgärtner, V R Jacobs, et al.
Breast Cancer Research and Treatment|January 9, 2009
Cost-utility analysis for advanced breast cancer therapy in Germany: results of the fulvestrant sequencing modelMichael Patrick Lux, M Hartmann, C Jackisch, et al.
Oncogene|June 29, 2000
Rac1 in human breast cancer: overexpression, mutation analysis, and characterization of a new isoform, Rac1bA Schnelzer, D Prechtel, U Knaus, et al.
Cancer Research|March 14, 2001
Hydroxamate-type matrix metalloproteinase inhibitor batimastat promotes liver metastasisA Krüger, R Soeltl, I Sopov, et al.
The International Journal of Biological Markers|April 14, 2000
Long-term follow-up confirms prognostic impact of PAI-1 and cathepsin D and L in primary breast cancerN Harbeck, U Alt, U Berger, et al.
Anticancer Research|August 15, 1998
Identification of low-risk node-negative breast cancer patients by tumor biological factors PAI-1 and cathepsin LC Thomssen, P Oppelt, F Jänicke, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 5, 2013
The Patient's Anastrozole Compliance to Therapy (PACT) Program: a randomized, in-practice study on the impact of a standardized information program on persistence and compliance to adjuvant endocrine therapy in postmenopausal women with early breast cancerP Hadji, M Blettner, N Harbeck, et al.
Pageof 15

Showing results (31-40 of 148) with videos related to

Sort By:
Pageof 15
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|March 19, 2014
Timing of radiotherapy following breast-conserving surgery: outcome of 1393 patients at a single institutionS Corradini, O M Niemoeller, M Niyazi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 23, 2017
Pooled analysis of two randomized, double-blind trials comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancerK Blackwell, P Gascon, C M Jones, et al.
Oncology Reports|April 6, 2006
Application of intrathecal trastuzumab (Herceptintrade mark) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancerH J Stemmler, M Schmitt, N Harbeck, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 12, 2007
Management of venous port systems in oncology: a review of current evidenceS Vescia, A K Baumgärtner, V R Jacobs, et al.
Breast Cancer Research and Treatment|January 9, 2009
Cost-utility analysis for advanced breast cancer therapy in Germany: results of the fulvestrant sequencing modelMichael Patrick Lux, M Hartmann, C Jackisch, et al.
Oncogene|June 29, 2000
Rac1 in human breast cancer: overexpression, mutation analysis, and characterization of a new isoform, Rac1bA Schnelzer, D Prechtel, U Knaus, et al.
Cancer Research|March 14, 2001
Hydroxamate-type matrix metalloproteinase inhibitor batimastat promotes liver metastasisA Krüger, R Soeltl, I Sopov, et al.
The International Journal of Biological Markers|April 14, 2000
Long-term follow-up confirms prognostic impact of PAI-1 and cathepsin D and L in primary breast cancerN Harbeck, U Alt, U Berger, et al.
Anticancer Research|August 15, 1998
Identification of low-risk node-negative breast cancer patients by tumor biological factors PAI-1 and cathepsin LC Thomssen, P Oppelt, F Jänicke, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 5, 2013
The Patient's Anastrozole Compliance to Therapy (PACT) Program: a randomized, in-practice study on the impact of a standardized information program on persistence and compliance to adjuvant endocrine therapy in postmenopausal women with early breast cancerP Hadji, M Blettner, N Harbeck, et al.
Pageof 15